Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Haberecker, M; Rüschoff, JH; Andriakopoulou, C; Gray, SG; Nackaerts, K; De, Perrot, M; Brcic, L; Nadal, E; Tsimpoukis, S; Ampollini, L; Aerts, JG; Kirschner, MB; Monkhorst, K; Weynand, B; Bavaghar-Zaeimi, F; Samarzija, M; Llatjos, R; Finn, SP; Silini, E; Von, Der, Thüsen, J; Vagenknecht, P; Tsourti, Z; Kerr, KM; Kammler, R; Peters, S; Baas, P; Opitz, I; Stahel, RA; Curioni-Fontecedro, A, , ETOP, Mesoscape, Consortium;TransSCOT, Consortium.
Prevalence and Clinical Association of CD276 (B7-H3) Expression in Pleural Mesothelioma: Results From the European Thoracic Platform Mesoscape Project.
JCO Precis Oncol. 2025; 9:e2400675
Doi: 10.1200/PO-24-00675
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Brcic Luka
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- PURPOSE: CD276 (B7-H3) is an immunoregulatory protein that plays an important role in the inhibition of T-cell function. CD276 is overexpressed on a variety of human solid cancer cells with limited expression in normal tissues, making it an appealing target for innovative cancer immunotherapy approaches. Pleural mesothelioma (PM) is a highly aggressive disease with a need for new treatment options. Our objective was to investigate the expression of CD276 in the multicenter PM cohort of the European Thoracic Oncology Platform Mesoscape project and correlate the results with annotated clinical data. MATERIALS AND METHODS: Using tissue microarrays (TMAs), the expression of CD276, assessed using a semiquantitative aggregate H-score method on the membrane (and secondarily in the cytoplasm), was correlated with clinicopathologic characteristics and survival outcome. RESULTS: CD276 immunohistochemistry results were available for 353 patients, with mostly epithelioid histology (71%). Membranous CD276 expression was present in 86%. High membranous CD276 expression (H-score ≥the median H-score of 120) was significantly more common in females (P = .0029; 71% v 47%) and in epithelioid histology (P < .001; 59% v 29%), whereas no significant association in clinical outcome (overall survival [OS]/progression-free survival) was found. Cross-validation of the TMA method using whole sections revealed a moderate agreement for membranous assessment (Cohen's kappa = 0.47) and a lower agreement for cytoplasm assessment (Cohen's kappa = 0.37). In an exploratory analysis, high cytoplasmic CD276 expression was associated with worse prognosis (OS, log-rank P = .043), but was not significant when adjusting for other clinical variables. CONCLUSION: Although no prognostic value of CD276 expression was found, its high membranous expression (86%) in the PM samples of the study supports further research of its potential as a therapeutic target for this disease.
- Find related publications in this database (using NLM MeSH Indexing)
- Humans - administration & dosage
- B7 Antigens - administration & dosage
- Female - administration & dosage
- Male - administration & dosage
- Aged - administration & dosage
- Middle Aged - administration & dosage
- Pleural Neoplasms - metabolism
- Mesothelioma - metabolism
- Europe - administration & dosage
- Aged, 80 and over - administration & dosage
- Adult - administration & dosage
- Prevalence - administration & dosage
- Mesothelioma, Malignant - administration & dosage